|
Orthologous residues
|
|
PLCG1 (human): Y783‑p, PLCG1 iso2 (human): Y783‑p, PLCG1 (mouse): Y783‑p, PLCG1 (rat): Y783‑p, PLCG1 (cow): Y783‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
Jurkat (T lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
anti-CD3, saturated fatty acid
|
|
|
|
increase
|
|
|
polyunsaturated fatty acid, anti-CD3
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, induced
|